Extracellular vesicles are small particles released by cells that carry biological molecules. Those derived from mesenchymal cells hold significant therapeutic potential in regenerative medicine. However, their translation from laboratory to clinic requires standardized manufacturing processes compatible with pharmaceutical quality.
A study published in iScience, led by the Heart Failure and Cardiac Regeneration (ICREC) group at IGTP and BST, presents a platform integrating bioreactor culture with concentration and purification techniques. The process uses chemically defined, animal-component-free cultures and has been developed at an intermediate scale semi-automatically.
The platform complies with Good Manufacturing Practice (GMP) standards and addresses the challenge of having robust and reproducible production processes for extracellular vesicle-based therapies.
“"For extracellular vesicles to be used in future therapies, we need manufacturing processes that yield safe products with consistent quality. This platform helps us advance in that direction."
“"This collaborative project reflects the firm commitment of the Blood and Tissue Bank to the clinical translation of new developments with therapeutic potential. Integrating robust, reproducible, and scalable processes is fundamental to transforming innovative research into safe, tangible, and accessible therapies for patients."
The results pave the way for the potential clinical application of these products, particularly in regenerative medicine and the development of therapeutic strategies for cardiovascular diseases.
